Trial Profile

A phase II study of ALN-APP in Alzheimer's disease patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mivelsiran (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use

Most Recent Events

12 Jan 2025 According to Alnylam Pharmaceuticals media release, company plans to initiate this Phase 2 study in Alzheimers disease in the second half of 2025.
18 Dec 2023 New trial record
13 Dec 2023 According to Alnylam Pharmaceuticals media release, the company plans to initiate this study at or around year-end 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com